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Infectious diseases caused by arboviruses (viruses transmitted by arthropods) are undergoing unprecedented epidemic
activity and geographic expansion. With the recent introduction of West Nile virus (1999), chikungunya virus (2013) and
Zika virus (2015) to the Americas, stopping or even preventing the expansion of viruses into susceptible populations is
an increasing concern. With a few exceptions, available vaccines protecting against arboviral infections are nonexistent
and current disease prevention relies on vector control interventions. However, due to the emergence of and rapidly
spreading insecticide resistance, different disease control methods are needed. A feasible method of reducing
emerging tropical diseases is the implementation of vaccines that prevent or decrease viral infection in the vector.
These vaccines are designated ‘transmission blocking vaccines’, or TBVs. Here, we summarize previous TBV work,
discuss current research on arboviral TBVs and present several promising TBV candidates.
Keywords: Transmission blocking vaccines, Arbovirus, Arthropod, VectorsBackground
Infectious disease represents one the leading causes of
mortality worldwide but it is especially problematic in
tropical countries [1]. Among all infectious agents,
viruses have been responsible for at least three major
pandemics: smallpox, the “Spanish flu” (influenza virus)
and the ongoing HIV/AIDS (human immunodeficiency
virus) epidemic with more 30 million people affected
globally [2, 3]. Smallpox infection was one of the major
causes of death worldwide, with a death toll between
300 and 500 million people. In the late 1700s, Dr
Edward Jenner pioneered an immunization practice,
which eventually led to the eradication of this disease
in 1980 [4, 5]. The principle of the smallpox vaccine
and other viral vaccines is to educate the body with a
non-pathogenic but closely related microorganism.
Consequently, this establishes immunological memory,
strengthens the immune system and prevents future
attacks from the invading virus [6, 7].
Improving living conditions plays an important role in
decreasing the global incidence of viral diseases but the
implementation of vaccines has also had a significant
impact [8, 9]. To date, several viral diseases have been* Correspondence: blondono@uscmed.sc.edu
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campaigns. In the early 2000s, measles and rubella
were eliminated from the United States and had lower
incidence rates worldwide due to aggressive vaccination
efforts [10, 11]. However, the re-emergence of mutant and
drug resistant strains still poses a threat for the eradication
of diseases like polio [12, 13], especially in areas with
low vaccination coverage due to religious beliefs, lack of
educational campaigns or general mistrust of health care
workers providing the vaccines [13, 14]. Consequently,
proper and timely education of the public is of pivotal
importance in assuring and maintaining the efficacy of
vaccination programs [15]. Vaccine efficacy and safety has
improved considerably since Dr Jenner’s rudimentary
smallpox vaccine through the use of several new techno-
logies. These developments include the production of
live/attenuated, inactivated, toxoids and subunit/conjugate
vaccines aiming to induce long lasting immunological
memory in order to respond quickly to the invading
pathogen [7].
The majority of available vaccines protect against
communicable viral diseases; however, for the vast majo-
rity of ‘arboviruses’, the name given to viruses transmitted
by arthropods (arthropod-borne viruses), there is no
vaccine alternative yet. The exceptions of this rule include
the 17D yellow fever virus (YFV) vaccine and the newlyle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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[16, 17]. For decades, the main control method of arbovi-
ruses has relied on insecticide treatment of houses, reduc-
tion of breeding sites and limiting the vector-host contact
(i.e., using a barrier protection like bed nets) [18–20]. New
control strategies are needed due to increased insecticide
resistance and the spreading of infectious arthropods to
new areas [21, 22]. Unfortunately, insecticide resistance
has spread to most countries endemic for vector-borne
diseases [23]. Insect genetics and the continued/indiscri-
minate use of insecticides have largely contributed to the
selection of resistant arthropods threatening the success
of disease control programs [24, 25]. Fortunately, exten-
sive research has shed some light onto the mechanism
leading to resistance. For instance, insects can become
insensitive to insecticide by metabolic resistance (metabo-
lizing the insecticide faster than insecticide-sensitive
strains), target modification (the insecticide-target molecule
may change the structure/sequence) or behavioral modi-
fications (indoor feeders changing to outdoor feeders)
[26–28]. The presence of resistant mosquitoes in an area
endemic for vector-borne diseases have a deleterious
impact on public health control programs aimed to pro-
tect the population for exposure to infective arthropod
bites [25]. Vector insecticide resistance also has a negative
impact on economies as it pushes governments to use
different and more expensive insecticides as well as
requiring continuous re-treatment of areas [29, 30].
Climate variability has a direct impact on disease trans-
mission since the life-cycle of the arthropod vector as well
as the pathogen extrinsic incubation periods (EIPs), which
depend on factors like temperature and humidity [31, 32],
For instance, an increase in temperature has been associated
with shorter extrinsic incubation periods and higher vectorFig. 1 Schematic representation of the Aedes aegypti mosquito geographicmortality [33–35]. Changes in vegetation and precipitation
may induce an increase in mosquito densities in such a way
that both factors are important predictors of mosquito abun-
dance [36, 37] An example of the expansion of Aedes aegypti
mosquitoes towards more temperate regions is depicted in
Fig. 1 [38–40]. Tick life-cycle is also affected by climate
fluctuations, helping several species to expand its territory to
new higher altitudes due to warmer seasons [41]. Likewise,
environmental and social factors also have a great impact on
vector-borne diseases, associated with land use, water stor-
age and seasonal work along with global travel all contribute
to the rapid movement of human carriers and infected
mosquitoes worldwide disseminating diseases [42–44].
Designing vaccines that prevent the pathogen from
completing its life-cycle in the vector is one approach to
halting transmission to humans [45]. Such vaccine alterna-
tives have received the name of transmission blocking
vaccines (TBVs). Different from traditional vaccines, TBVs
aim to prevent infection in the transmitting vector rather
than in the human host. They are also known as “altruistic
vaccines”, where the person receiving the vaccine may or
may not be protected from infection but may prevent
their neighbors from getting the disease [46, 47]. Interes-
tingly enough, protecting one’s neighbor could actually,
in the end, prevent one’s own new infection due to a
phenomenon called “herd immunity” [48]. Since TBVs
will have long-term effects they have to meet certain
criteria to be widely accepted and implemented in the
field. For example, besides having a high efficacy of infec-
tion prevention to the arthropod vector, care must be
taken to avoid any cross-reactions or autoimmune disease
in humans [49]. In addition, one of the most difficult chal-
lenges for TBVs is the maintenance of high antibody titers
in vaccinated individuals due to the lack of naturalal expansion from 1980 to 2016
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antigens are not normally found in the human but in the
mosquito or tick vector [46, 47]. One way to solve this
problem is through the use of adjuvants. Thus, significant
effort has been put towards the design and implementation
of new and safe adjuvants compatible with the vaccine
formulations against mosquito, tick, or pathogen proteins
[50, 51]. Adjuvants like the nanoparticle-forming exopro-
tein from Pseudomonas aeruginosa A (EPA), the outer-
membrane protein complex (OMPC) of Neisseria meningi-
tidis serogroup B and the IMX313, a chicken complement
C4b-binding protein oligomerization domain, have shown
to significantly increase antibody responses against the
conjugated peptides [52, 53]. A substantial review on other
adjuvants and their mechanism of action can be found in
Bergmann-Leitner et al. [54].
There is a growing concern regarding emerging and re-
emerging arboviruses in many parts of the world. In the last
decade, the American continent has suffered the introduc-
tion of several mosquito-transmitted viruses. In the late
1990s, West Nile virus (WNV) was introduced to New York
City. Recently, Central and South America have been the
focus of the latest chikungunya virus (CHIKV) and Zika
virus (ZIKV) epidemics [55, 56]. Interestingly, several TBVs
targeting the transmission of malaria are currently in clinical
trials [57, 58], suggesting that TBVs are a feasible method
for limiting the spread of insect-borne diseases such as
those caused by arboviruses. TBVs are an attractive tool to
decrease arbovirus transmission, especially in the absence of
specific antiviral treatments to prevent severity in high-risk
populations, such as the elderly and pregnant women. The
aim of this paper is to summarize the current TBV candidatesFig. 2 Representation of the principal mechanisms of TBVs. a In the case o
the vector will ingest antibodies against the target protein during blood fe
TBV, antibodies are directed against proteins required for blood digestion o
host, those antibodies may kill the vectors or decrease their capacity to laidfor arboviruses and the most promising molecules that
could be used in future TBV vaccine developments.
Potential TBV impact on arboviral transmission
There are approximately 3.5 billion people at risk of con-
tracting diseases transmitted by arthropods. More specific-
ally, one sixth of the total infectious diseases worldwide are
spread by arthropod vectors [59]. There are even some
cases where a single arthropod species is able to transmit
more than one human pathogen in a given time. This is the
case of Aedes aegypti, a prolific vector of many arboviruses
including DENV, CHIKV, ZIKV and YFV [60–62]. Thus, a
tool targeting transmission capacity in the vector rather
than a single anti-microorganism human vaccine could be
a practical control method for these diseases [60, 63].
Since the objective of the TBV vaccine is to halt
new infection in transmission-competent insects, several
approaches have been implemented to prevent infection
in the vector (Fig. 2). To specify, most current TBV can-
didates focus on specific arthropod proteins while several
others target pathogen antigens [64]. For instance, poten-
tial TBVs against DENV and WNV infections are designed
using mosquito proteins required for viral infection of
the mosquito vector [65, 66]. Some of these proteins have
shown to be essential for virion attachment to the target
cells or for successful completion of the viral life-cycle
[67]. Conversely, other TBV candidates consist of mole-
cules required by the vector to obtain or digest nutrients
[68, 69]. Arthropod proteins carried by all members of the
species may have an effect on vector feeding or physio-
logical changes as well as impacting transmission capacity
of all or several pathogens [70]. A summary of the mostf TBVs based on the vector proteins that interact with the pathogen,
eding inhibiting the pathogen entrance to cells. b In second type of
r egg production. Thus, when the arthropod feeds on a vaccinated
eggs
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Table 1.
TBV to control arbovirosis transmitted by
mosquitoes
West Nile virus
WNV is a zoonotic arbovirus member of the Flavivirus
genus and it is naturally maintained in an enzootic cycle
between birds and mosquitoes [71]. Birds are the natural
reservoir for WNV able to develop a transient high
viremic titer allowing transmission of WNV to mosqui-
toes that preferentially feed on these birds. Migratory
birds are of importance since they can carry the virus
from one region to another [72]. Most bird infections
with WNV results in non-fatal outcomes conferring a
permanent immunity after infection [73]. However,
several bird species, specially from the family Corvidae,
do not usually survive WNV infection and are useful
in tracking virus spread through dead-bird surveillance
programs [74].
In addition, WNV virus infects horses and can be trans-
mitted to humans in close contact with these animals
[75]. Humans and horses are infected as incidental dead-
end hosts with insufficient viremia to perpetuate the
transmission cycle, but this virus is able to cause small
outbreaks in naïve populations [76]. Before 1990, this
disease occurred sporadically as a minor risk for humans.
The first cases of severe WNV were reported between
1994 and 1996 during the Algeria and Romania outbreaks
where neurological complications were reported in
several cases [77, 78]. WNV has now spread globally
and although majority of infections are asymptomatic,
elder populations as well as immune-compromised
individuals are at high risk of severe disease [79]. The inci-
dence of WNV has also increased worldwide in the last
decade and now is the major cause of human encephalitis
in USA [80, 81]. One of the major epidemics in USATable 1 Main arthropod protein candidates for TBVs to control arbo
Candidate molecule Arthropod host Function
mosGCTL-1 Aedes aegypti Involved in WNV attachment by
interacting with PTP-1 [65]
mosGCTL-3 Aedes aegypti Modulates virus entrance by interac
with the DENV Envelope protein [6
CRVP-379 Aedes aegypti Interacts with the putative DENV re
prohibitin [63, 102]
CPB-1 Aedes aegypti Midgut antigen. Interacts with the
Envelope protein [100, 101]
64-TRP Rhipicepalus
appendiculatus
Salivary antigen. Secures ticks mout
parts during blood feeding [136, 13
Bm-86 Rhipicephalus
microplus
Midgut antigen [131, 134]
PpChit-1 Phlebotomus
papatasi
Aids maturation of peritrophic matrioccurred in 2012 with more than 5000 human cases
reported in 48 states that resulted in 286 deaths [82].
Several species are important vectors of WNV in USA,
with Culex pipiens as one of the most important vectors,
followed by Culex quinquifasciatus and Culex tarsalis
[83]. However, at least 59 mosquito species have been
identified as potential vectors and ten species have been
confirmed as important vectors [84]. Consequently, con-
tinued surveillance as well as preventive methods are in
need to control WNV infections in USA and worldwide.
Recent studies have demonstrated the role of C-type
lectins in the establishment of Flavivirus, including WNV
infection, in both mammals and the mosquito vector
[85, 86]. For instance, Cheng et al. (2010) demonstrated
that the knockdown of mosGCTL-1, or the feeding of
mosquitoes with specific antibodies against the Aedes
aegypti protein mosGCTL-1, significantly reduced WNV
infection in both Aedes and Culex mosquitoes [65]. An
upregulation of this protein is induced upon infection with
WNV [65]. This study also showed that the Ae. aegypti
C-type lectin (mosGCTL-1) interacts with WNV in a way
that facilitates infection. MosGCTL-1 protein is recruited
by mosPTP-1, an Ae. aegypti mosquito homolog of
human CD45, which is a member of the of the protein
tyrosine phosphatase (PTP) family. The interaction between
mosGCTL-1 and mos-PTP-1 allows viral attachment to
cells and enhances viral entry. Furthermore, both proteins
are critical for WNV infection as demonstrated in expe-
riments with Culex quinquifasciatus, the most competent
vector for this virus [67]. Taking all this information
together, mosGCTL-1 could be a potential target for a
TBV against WNV.
Dengue virus
Dengue is currently one of the most important viral
diseases of the tropics causing high morbidity and mortality
in pediatric populations [87, 88]. There are four distinctviruses
Effect on disease Available as vaccine
Reduces WNV infection in mosquitoes No
ting
7]
Reduce DENV infection in mosquitoes No
ceptor Blocks DENV infection in midgut No
DENV Reduces DENV infection in mosquito No
h
7]
Reduces vector-host contact. Induces
death of blood feed ticks
No
Reduces blood uptake and vector-host
contact
Yes
x [159] Reduced sand fly life span and fecundity No
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mosquitoes. While genetically closely related, each serotype
differs in antigenicity, thus cross-protection is limited
[89–91] and infection with any serotype induces lifelong
immunity to only that specific serotype [89, 92]. While the
majority of DENV infections result in little or no disease,
a small proportion progresses to severe forms: dengue
with warning signs and severe dengue (WHO 2009) also
known as dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS) [93]. The etiology of severe dengue
is not completely understood; however, one of the most
accepted theories suggests that dengue pathogenesis is
related to antibody-enhanced infection (ADE) of DENV in
Fc-receptor bearing target host cells [90]. Epidemiological
studies suggest that antibodies to each of the four DENV
are capable of enhancing further DENV infections. This
phenomenon has been studied extensively in vitro and
modeled in mice [94–97] and it is currently one of the
challenges for the implementation of a protective vaccine
against DENV infection.
An effective TBV for DENV should be able to block
infection of all serotypes to prevent an increase in the
severity of cases. Recent research has discovered several
mosquito molecules with a critical role in DENV cell
entry and replication [98, 99]. As seen in WNV, several
C-type lectins have been associated with Ae. aegypti
and DENV infection. For instance, as mosGCTL-1
mediates the attachment of WNV on cell membranes, the
Ae. aegypti, mosGCTL-3 is involved in DENV-2 infec-
tion. A recent study showed that mosGCTL-3 interacts
directly with DENV envelope protein (Ep) and its gene
expression is significantly upregulated upon DENV2
infection. After immunization, antibodies directed against
mosGCTL-3 were able to disrupt mosquito infection with
DENV-2 [67]. This indicates that GCTL-3 may be a
suitable candidate for the development of a TBV.
Several suitable avenues in the search for TBV targets in
mosquitoes have been explored. One approach, protein
interaction screening, revealed that the Ae. aegypti
carboxypeptidase B1 (CPB1) is one of the predominant
midgut proteins interacting with the DENV-2 Ep [100].
Previous studies suggested that CPB1 is upregulated after
a blood meal and it is involved in the intra- and extracel-
lular accumulation and secretion of infectious DENV-2
particles [101]. CPB1 was found throughout the cells but
the Ep-CPB1 complex was only observed in the endoplas-
mic reticulum close to the nuclei. Tham et al. (2014)
suggested that CPB1 is involved in regulating viral repli-
cation and the release of virion particles from midgut cells
[100]. In the presence of CPB1, virus released from
infected cells is predominantly immature, decreasing the
chances for the virus to colonize salivary glands, and
consequently reducing virus transmission to humans and
other mammals [100].Another protein candidate for a TBV against DENV
infection is the putative cysteine rich venom protein 379
(CRVP379). CRVP379 expression is also upregulated by
infection with DENV. Our group recently published that
silencing CRVP379 significantly reduced DENV infec-
tion in Ae. aegypti mosquitoes. Additionally, we have
found that CRVP379 is required for DENV infection
and that it directly interacts with prohibitin, a putative
receptor for DENV in Aedes spp. Blocking CRVP379
with specific antibodies recognizing the mosquito protein
significantly reduced DENV infection in mosquitoes [66].
Additionally, CRVP379 has very low homology to any
mammalian or human proteins. Since CRVP379 was
found to be upregulated in WNV and YFV infections, we
speculate that this protein is also required for infection of
mosquitoes with these diseases; thus, antibodies against
CRVP379 may also impact infection and subsequent
transmission of other closely related flaviviruses [102].
If this hypothesis is correct, a TBV based on CRVP379
could have an enormous impact in places with concurrent
transmission of these arboviruses, which is the case in
most South and Central American countries. We are
currently testing this hypothesis in our laboratory.
Rift Valley fever virus
Rift Valley fever virus (RVFV) is mainly maintained in
the environment by transmission between animals (wild
or domestic) and several mosquito species including Ae-
des, Culex and Anopheles [103, 104] although occasional
transmission by other hematophagous insects has been
reported [105, 106]. Most human cases of RVFV are
mild; however, a small proportion progresses to the
severe forms of the disease manifesting as meningo-
encephalitis or hemorrhagic fever [107, 108].
Although no TBV vaccine has been evaluated to control
RVF infections, significant advances have been made in
the biology of the mosquito vectors trying to block trans-
mission of other diseases. For instance, the most promi-
sing Anopheles protein with potential of impacting RVFV
transmission to date is the midgut protein alanyl amino-
peptidase N (AnAPN1) [109]. This protein is present
on the Anopheles gambiae midgut apical surface and
it is believed to function as a receptor for Plasmodium
ookinetes. Antibodies against AnAPN1 are able to inhibit
P. falciparum parasite load [110]. Further investigation is
needed to evaluate the effect of this protein in the deve-
lopment of RVFV in Anopheles and its further transmis-
sion to the vertebrate host.
TBVs with the potential for targeting multiple
diseases transmitted by other arthropods
The blockage of arthropod proteins by the antibodies
elicited against them through vaccines may have an
impact not only on the lifespan of the arthropod vector
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ganisms they carry [111, 112]. These are vector-derived
molecules involved in food digestion or feeding capacity
[64]. Following, we present a list of candidates developed
with the purpose of decreasing vector-host contact or
halting midgut infection and salivary gland invasion.
Ticks
While mosquitoes represent the main vectors of human
disease, ticks can also transmit several human pathogens
and are the most important transmission vectors in
veterinary medicine, serving as principal vectors of zoo-
notic diseases [113]. In blood feeding arthropods, midgut
protein targets are preferred as this is the first organ in
contact with blood factors and the newly invading patho-
gens [114, 115]. In mosquitoes, blood can remain in the
midgut for at least 24 h before all factors start degrading
due to the action of digestive enzymes. On the contrary,
tick blood digestion may take a few days [116]. Several tick
species can feed and regurgitate during the blood meal
uptake process increasing the chances of pathogen trans-
mission, especially because undigested blood in the tick
midgut can be stored for long periods allowing enough
time for the virus to interact with epithelia [117–120].
Different from other blood-sucker arthropods, tick feeding
process is characterized by digestion of blood at the intra-
cellular vesicles of gut cells [121]. Since this phenomenon
is special characteristic of ticks, there are current directed
towards the characterization of digestive enzymes and
feeding regulation that could lead to new alternative for
TBV design [122, 123].
Tick infestation represented a significant nuisance for
the cattle industry. Therefore, a great deal of effort was
put into the design of non-chemical insecticides and a
few vaccines are commercially available. For instance,
Rhipicephalus spp. (formerly Boophilus spp.) is a major
cattle pest in tropical and subtropical countries [124, 125].
Infestations with Rhipicephalus microplus (cattle tick),
severely impacts the cattle by inhibiting weight gain and
decreasing milk production [125, 126]. Although there are
reports that this species has been eradicated from
most of USA, there are still cases of infestation leading
to quarantine in bordering regions of Texas and California
with Mexico [127]. Constant surveillance is implemented
by the USDA Cattle Fever Tick Eradication Program
to avoid the incursion of R. microplus into USA. The
program consists of frequent patrolling/inspection of
ranches in the Rio Grande area as well as acaricide
prophylactic treatment and detention of smuggled live-
stock from Mexico [127, 128].
Rhipicephalus microplus is an important vector of
Babesia bovis and Anaplasma marginale infections
[129, 130]. In 1989, Willadsen et al. launched a new con-
cept for the treatment of tick infestation. They described atick gut antigen protein, Bm-86, and found that antibodies
raised against this protein were able to reduce blood
uptake and egg production of Rhipicephalus ticks [131].
In the following years, Gavac™ (Latin America) and Tick-
GARD (Australia) vaccines based on the Bm-86 protein
were commercially available. Antibodies against Bm-86
bind to the surface of the tick’s intestinal epithelial cells,
which causes cell lysis. This leads to a reduction in the
reproduction efficiency of Rhipicephalus ticks [132]. This
vaccine also induces comparable antibody levels in diffe-
rent cattle breeds [133]. Interestingly, after the imple-
mentation of Gavac™ in Cuba, several studies showed a
significant reduction in the incidence of tick-borne cattle
diseases and subsequently, mortality [134, 135]. Currently,
TickGARD and Gavac™ vaccine use is restricted to a small
group of countries. However, effectiveness of these vac-
cines is restricted to Rhipicephalus ticks and efficacy may
vary among tick strains [70, 135]. The development of
new vaccines targeting other tick genera is needed.
Several anti-tick vaccine alternatives have been pro-
posed. One of them is a vaccine based on a 15-kDa tick
saliva protein, 64TRP. The 64TRP acts like a ‘cement’
and helps the tick to secure the mouthparts on the host
skin during feeding [136]. This protein was described in
the tick species Rhipicephalus appendiculatus and it
induces a strong humoral response [68]. In vivo studies
in rodents have shown that antibodies against 64-TRP
not only impair tick feeding but also cross-react with
midgut antigens, resulting in the death of engorged ticks.
Furthermore, antibodies against 64-TRP have shown to
be effective against both adult and immature stages of
several tick species [136, 137]. Labuda et al. [137] demon-
strated that 64-TRP induces an immune response suitable
for a TBV that has protective functions comparable to
TickGARD against TBEV. Other targets have also been
proposed to control tick infestation and prevent disease
transmission. For a more complete catalogue of anti-tick
vaccine alternatives please review the study by Merino
et al. [111].
Another tick of medical importance in USA is the
lone star tick, Amblyomma americanum, a common para-
sitic arthropod of cattle and dogs among other species
[138, 139]. This species is an important vector of Heart-
land and Bourbon virus, two emerging pathogens casing
severe disease in humans in several regions within USA
[140, 141]. One study was found in the literature address-
ing the possibility of a TBV vaccine to prevent transmis-
sion of diseases by the lone star tick. In this study, de la
Fuente et al. [142] identified several potential TBV can-
didates by RNAi-based screening of the A. americanum
cDNA library. The most promising candidates were
the subolesin and the interphase cytoplasm foci pro-
tein 45, 2G7. Cattle vaccinated with these proteins
showed a significant antibody production and reduction
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cases by Heartland and Bourbon viruses, more investiga-
tion is needed into potential vaccine targets that would
block their transmission to and from the vector.
Previous studies have shown that certain vertebrate
hosts have the ability to develop anti-tick immunity after
several exposures to a particular tick species [143]. Based
on this principle, the European group, the ANTIDotE
consortium, was created to develop TBVs against Ixodes
ricinus to fight the diseases transmitted by this tick
species. In contrast to the anti-Rhipicephalus vaccines
directed against the arthropod gut, ANTIDotE vaccines are
based on salivary antigens that have showed an impact on
vector feeding behavior and pathogen transmission [144].
In USA, Ixodes scapularis is known as an important
vector of Powassan virus (POWV) the causing agent of
Powassan encephalitis endemic in North America and
eastern Russia [145]. Mortality rate of Powassan ence-
phalitis is below 11 %. However, infection with POWV
may lead to severe neurological sequelae [145–147].
Incidence of Powassan encephalitis has increased in the
last fifteen years but it is still a ‘neglected’ tick-borne
disease in North America [148]. Most research on this
tick species is directed to stop other bacterial or parasitic
diseases transmitted by this species and yet there is little
research on transmission blocking vaccine being designed
to stop POWV transmission [149]. The ANTIDotE
approach may also lead to POWV candidates, especially
because, POWV is transmitted imbibed in tick saliva and
transmission occurs in the first hours of blood feeding
[150]. Since tick-borne diseases are in expansion, extensive
research is needed to characterize the factors involved in
tick-borne virus transmission to prevent new infections,
control spread and avoid emergence into new areas.
Sandflies and phleboviruses
Several arboviruses are transmitted by sandflies in both
Old and New World countries [151–154]. These viruses
belong to the genera Phlebovirus, Vesiculovirus and
Orbivirus [155, 156]. Most research on sand fly-based
TBVs is aimed to control leishmaniasis. However, it is
possible that the use of candidate proteins involved in
blood meal digestion, fecundity or life span of sandflies
may also have an impact on other diseases transmitted
by these arthropods [157, 158].
One example is chitinase 1 (PpChit-1), the midgut
protein of Phlebotomus papatasi. This protein is involved
in the maturation of the peritrophic matrix (PM), which is
of pivotal importance in blood digestion [157]. Previous
studies show that antibodies against this protein also
cross-react with other midgut proteins from different
Phlebotomus species [159]. Most importantly, treatment
with antibodies against PpChit-1 negatively impacts the
ability of sandflies to lay eggs. This is potentially caused byPM permeability changes induced by the attaching anti-
bodies. These changes affect nutrient absorption and egg
development [159].
Conclusions
In this review, we provide examples of new advances in
vaccine technology aimed to block or eliminate insect-
borne infectious diseases. Arboviruses are expanding not
only geographically but they are also able to invade and be
transmitted by a wide range of arthropods. At present,
there are no specific treatments and very few vaccines that
prevent most human arbovirus infections. Currently, pre-
vention of arbovirus infection mainly relies on insecticide
treatments, reduction of breeding sites and using barrier
protection, such as bed nets or insecticide-impregnated
clothing; however, these methods, although moderately
effective, are not enough. Recently we have seen Heartland,
CHIKV, and ZIKV virus outbreaks expand to the Americas
at a rapid rate. In this regard, TBVs have the potential to
decrease infection among certain populations while in-
creasing herd immunity, which makes them an attractive
tool to combat pathogen transmission and proliferation.
TBVs directed against specific arthropod molecules have
the potential to impact most of the pathogens transmitted
by a single vector. As with insecticides, there is always
the possibility of resistance development against TBV
vaccines, especially if genes with high selective pressure
are targeted. To avoid possible selection, TBVs should be
implemented along with other types of transmission con-
trol methods such as bed nets and insecticides to reduce
vector population. In addition, combining pathogen and
arthropod key target molecules in the same vaccine for-
mulation may increase TBV efficacy and will confer pro-
tection against infection and transmission.
Access to vaccination and coverage strategies are very
important factors in determining the effect of TBVs in
countries endemic for specific diseases. Developing coun-
tries with economically challenged health care systems will
greatly benefit from TBVs. Developing safe and affordable
vaccine alternatives, along with community education, will
improve the chances of reaching a broad distribution and
effective vaccine coverage.
In summary, although significant advances have been
made towards parasitic vector-borne diseases like malaria
and leishmaniasis, further research is needed in TBV
development for viral vector-borne diseases. TBVs repre-
sent a viable alternative to protect not only humans but also
livestock.
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